Jump Financial LLC Has $798,000 Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jump Financial LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report) by 52.0% in the 3rd quarter, Holdings Channel reports. The firm owned 14,650 shares of the medical instruments supplier’s stock after buying an additional 5,012 shares during the period. Jump Financial LLC’s holdings in LeMaitre Vascular were worth $798,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of LMAT. Captrust Financial Advisors increased its stake in LeMaitre Vascular by 555.3% in the first quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 522 shares in the last quarter. BluePath Capital Management LLC bought a new stake in LeMaitre Vascular in the third quarter valued at approximately $31,000. FMR LLC increased its stake in LeMaitre Vascular by 111.7% in the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in LeMaitre Vascular by 241.1% in the first quarter. Tower Research Capital LLC TRC now owns 1,354 shares of the medical instruments supplier’s stock valued at $70,000 after purchasing an additional 957 shares in the last quarter. Finally, Vestcor Inc bought a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $114,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 3.8 %

Shares of LMAT opened at $60.25 on Wednesday. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $68.67. The firm has a fifty day simple moving average of $56.04 and a 200 day simple moving average of $55.17. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 49.79, a PEG ratio of 2.91 and a beta of 0.86.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. JMP Securities assumed coverage on shares of LeMaitre Vascular in a research report on Monday, October 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Finally, KeyCorp assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday. They set a “sector weight” rating for the company. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.60.

Get Our Latest Analysis on LeMaitre Vascular

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 22,288 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $54.42, for a total transaction of $1,212,912.96. Following the transaction, the chief executive officer now owns 2,269,475 shares of the company’s stock, valued at $123,504,829.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO George W. Lemaitre sold 24,869 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $54.71, for a total value of $1,360,582.99. Following the transaction, the chief executive officer now owns 2,312,857 shares of the company’s stock, valued at $126,536,406.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 22,288 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $54.42, for a total value of $1,212,912.96. Following the completion of the sale, the chief executive officer now owns 2,269,475 shares of the company’s stock, valued at $123,504,829.50. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Company Profile

(Free Report)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Further Reading

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMATFree Report).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.